Trial Profile

Phase Ib Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Hepcidin Antagonist PRS-080#022-DP in Anemic Chronic Kidney Disease Patients Undergoing Hemodialysis

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 02 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs PRS 080 (Primary)
Indications Anaemia
Focus Adverse reactions
Sponsors Pieris Pharmaceuticals

Most Recent Events

13 Dec 2024 According to a Palvella Therapeutics media release, Pieris Pharmaceuticals merged with Palvella Therapeutics and will operate under the name Palvella Therapeutics, Inc.
19 Oct 2017 Planned End Date changed from 1 Jun 2017 to 31 Dec 2017.
09 Aug 2017 According to a Pieris Pharmaceuticals media release, the company has completed a Phase Ib single ascending dose study during the second quarter of 2017.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com